This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Dutch autoimmunity specialist Calypso Biotech BV has raised 20m in a Series A financing co-led by Gilde Healthcare and Inkef Capital and co-financed by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and […]
Evotec AG and the Helmholtz Centre for Infection Research (HZI) have joined platforms in order to find novel resistance-breaking antibiotics against Gram-negative bugs.
Researchers for the first time have found a way to prevent immune rejection of allogenic iPSC-derived cell and tissue transplants.
Swiss newco Arvelle Therapeutics has baged a $180m (159.1m) series A financing led by LSP. The company licenced the anti-epileptic candidate cenobamate (YKP3089) for $100m (88.4m) upfront from SK Biopharmaceuticals.
The market for bio-based building blocks and polymers showed moderate growth to 7.5 million tonnes in 2018 and will grow with a CGAR of 4% by 2023 reports German nova-Institute.
Swiss researchers have demonstrated a way to cure type I diabetes without cell transplantation. In model mice the reprogrammed non-islet cells from human pancreas
Biotech Campus Delft, Royal DSM and YES!Delft partner up have launched a Biotech Validation Lab to validate the business concepts of European biotech startups.
Gene therapy uniQure NV (Amsterdam) reported that factor IX levels of patients with severe hemophilia B raised to a mean of 38% of normal 12 weeks after a single injection of AMT-061.
Ose Immunotherapeutics has got the first milestone payment within its 272m deal with Servier inked in 2016.
Analyses of the stroma cell proteome have revealed how intratumoral hypoxia triggers the formation of dysfunctional blood vessels that block drugs from entering the tumour and push metastasis.